| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17127 R71744 |
Delteil - Beta-blockers, 2024 | Instrumental vaginal delivery | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 0.76 [0.62;0.92] C | 118/910 15,243/92,608 | 15,361 | 910 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17235 R72134 |
Kubota - Beta-blockers, 2023 | Vacuum or forceps | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) | 4.28 [0.47;39.02] C | 1/11 6/263 | 7 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13863 R54232 |
Mazkereth - Beta-blockers, 2019 | Instrumental delivery | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched | 1.46 [0.54;3.94] C | 10/153 7/153 | 17 | 153 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13902 R54406 |
Duan - Beta-blockers, 2018 | Vaginal‐assisted delivery | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 0.85 [0.69;1.05] C | 91/4,847 8,233/374,391 | 8,324 | 4,847 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13846 R54255 |
Darcie - Atenolol, 2004 | Forceps | late pregnancy | prospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 0.67 [0.11;4.11] C | 4/40 2/14 | 6 | 40 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 5 studies | 0.82 [0.70;0.95] | 23,715 | 5,961 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Asymetry test p-value = 0.1982 (by Egger's regression)
slope=-0.3217 (0.0931); intercept=0.9597 (0.5829); t=1.6464; p=0.1982
excluded